Edition:
United Kingdom

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

14.01USD
19 Aug 2019
Change (% chg)

-- (--)
Prev Close
$14.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
254,053
52-wk High
$43.85
52-wk Low
$11.89

Touchon, Pascal 

Dr. Pascal Touchon has been appointed as President, Chief Executive Officer, Director of the company, Effective June 24, 2019. Dr. Touchon, age 56, has served in roles of increasing responsibility at Novartis Oncology, a business unit of Novartis International AG, a global pharmaceutical company, since August 2015, most recently as Global Head Cell & Gene Therapies Oncology and a member of the Oncology Executive Committee. Previously, Dr. Touchon was Global Head Strategy, Business Development & Licensing, Oncology and a member of the Oncology Executive Committee. Prior to joining Novartis Oncology, Dr. Touchon spent nearly thirty years in the pharmaceutical industry in various companies, countries and leadership roles, most recently with Servier SAS, a privately owned French pharmaceutical company, as Senior Executive Vice President, member of the company Executive Committee and Head of Business Development and Licensing. Dr. Touchon holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France), a Diplôme d’Etudes Supérieures Spécialisées (DESS) in Management from Institut d’Administration des Entreprises (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Pascal Touchon

--

Utpal Koppikar

4,220,280

Joseph Newell

2,492,290

Mina Kim

3,384,430

Derrell Porter

1,510,390

Dietmar Berger

4,972,440
As Of  31 Dec 2018